Abstract
Correction: Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1158/0008-5472.can-16-1992
Journal: American Journal of Cancer | Publication Date: Aug 31, 2016 |
Correction: Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.
Join us for a 30 min session where you can share your feedback and ask us any queries you have